Mikel Moyer, Ph.D., has been named vice president of Molecular Discovery at Epizyme, Inc. He joins the company from the Broad Institute, where he was director of Medicinal Chemistry in the Stanley Center for Psychiatric Research. Prior to that, Dr. Moyer held leadership positions in medicinal chemistry groups at Pfizer for almost 20 years.
“Mike is a recognized leader in molecular discovery, and I welcome him to Epizyme, where his contributions will significantly advance our development of first-in-class medicines targeting histone methyltransferases (HMTs), a key group of epigenetic enzymes,” said Robert A. Copeland, Ph.D., executive vice president and chief scientific officer of Epizyme. “Mike’s appointment completes our highly experienced research leadership team, where he joins Dr. Victoria Richon, our vice president of Biological Sciences. Vicky led the team that discovered Zolinza at Memorial Sloan Kettering and was a co-founder of Aton, which was subsequently acquired by Merck.”